Get the Stockscreener App
0.8394
1.45%
-0.007
Tscan Therapeutics Inc stock is traded at $0.8394, with a volume of 41,547.
It is down -1.45% in the last 24 hours and down -5.31% over the past month.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$0.8464
Open:
$0.8697
24h Volume:
41,547
Relative Volume:
0.06
Market Cap:
$54.63M
Revenue:
$9.14M
Net Income/Loss:
$-124.31M
P/E Ratio:
-0.8768
EPS:
-0.9573
Net Cash Flow:
$-125.43M
1W Performance:
-8.82%
1M Performance:
-5.31%
6M Performance:
-26.83%
1Y Performance:
-55.40%
1-Day Range:
$0.833
$0.892
1-Week Range:
$0.8341
$0.97
52-Week Range:
$0.8251
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.836 | 55.31M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
478.71 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
660.02 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.73 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.19 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
268.83 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
TScan’s TSC-101 Trial: A New Cell Therapy Bet in Transplant Oncology - TipRanks
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
Cellares and Sonoma partner to automate cell therapy manufacturing - Yahoo Finance
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - AOL.com
A Quick Look at Today's Ratings for TScan Therapeutics(TCRX.US), With a Forecast Between $5 to $7 - Moomoo
TScan Therapeutics (TCRX) Morgan Stanley 23rd Annual Global Healthcare Conference summary - Quartr
TScan Therapeutics (TCRX) Q4 2025 earnings summary - Quartr
TScan Therapeutics Inc (TCRX) Institutional Confidence - TradingKey
Enterprise value to EBITDA forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics (TCRX) Stock Analysis Report | Financials & Insights - Benzinga España
Enterprise value to EBIT forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics at H.C. Wainwright: phase iii push gains pace By Investing.com - Investing.com Canada
TScan Therapeutics at H.C. Wainwright: phase iii push gains pace - Investing.com
Enterprise value to revenue forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
Price to sales forward of TScan Therapeutics, Inc. – BOATS:TCRX - TradingView
Price to earnings forward of TScan Therapeutics, Inc. – BOATS:TCRX - TradingView
TScan Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRX) - TradingView
TCRX Forecast — Price Target — Prediction for 2027 - TradingView
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS) - The Globe and Mail
H.C. Wainwright reiterates Tscan stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Tscan stock rating on trial data By Investing.com - Investing.com South Africa
TCRX Reiterated by Wedbush -- Price Target Maintained at $5.00 - GuruFocus
TCRX Reiterated by Needham -- Price Target Maintained at $6.00 - GuruFocus
TScan Therapeutics Price Target Maintained With a $6.00/Share by Needham - Moomoo
H.C. Wainwright Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Sahm
TScan reports Phase 1 data for TSC-101 blood cancer trial - grafa.com
Form 8K Tscan Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial - TipRanks
TScan reports trial data for blood cancer treatment TSC-101 - Investing.com
TScan reports trial data for blood cancer treatment TSC-101 By Investing.com - Investing.com Australia
TCRX: Cohort C results support advancing TSC-101 to Phase 3, showing high efficacy and safety - TradingView
TScan Therapeutics (TCRX) shows strong TSC-101 Phase 1 data, plans pivotal trial - Stock Titan
TScan Therapeutics Announces Positive Initial Data from - GlobeNewswire
Number of shareholders of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics (TCRX) Edges Higher Amid Support Test: Key Levels to WatchFibonacci Time Zone - dars.gov.et
TScan Therapeutics Inc (TCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TScan Therapeutics Inc (TCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TScan Therapeutics Inc (TCRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc (TCRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TScan Therapeutics Inc (TCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TScan Therapeutics (TCRX) Declines Sharply as Biotech Sector Headwinds IntensifySector Sentiment - newsline.com
Cellares and TScan to assess automated manufacturing of TSC-101 therapy - Yahoo Finance
Cellares, TScan Partner to Automate Manufacture of TCR-T Candidate - Contract Pharma
Cellares, TScan to evaluate automated manufacturing for TSC-101 By Investing.com - Investing.com Australia
Cellares, TScan to evaluate automated manufacturing for TSC-101 - Investing.com
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):